Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.37 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL588253 | 0.99 | CA1 (0.39) | CA1CA2CA4CA9DPP4 | |
| Hydrochloric Acid SCHEMBL588492 | 0.99 | CA1 (0.39) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL5359873 | 0.80 | PARP1 (0.55) | CA1CA2CA4CA9DPP4 | |
| SCHEMBL587766 | 0.74 | NR1H2 (0.48) | DPP4 | |
| SCHEMBL587767 | 0.74 | NR1H2 (0.48) | DPP4 | |
| Hydrochloric Acid SCHEMBL588562 | 0.73 | CHIT1 (0.36) | CA1CA2CA4CA9CHIT1 | |
| Hydrochloric Acid SCHEMBL588097 | 0.73 | CHIT1 (0.36) | CA1CA2CA4CA9CHIT1 | |
| Hydrochloric Acid SCHEMBL588620 | 0.73 | NR1H2 (0.48) | DPP4 | |
| Hydrochloric Acid SCHEMBL588254 | 0.73 | NR1H2 (0.48) | DPP4 | |
| Hydrochloric Acid SCHEMBL588621 | 0.73 | NR1H2 (0.48) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963296-B1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2012-02-15 | — | — | EP | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | HRH4, HRH1, HRH2 | CA1 1008/4885CA2 467/4885CA4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.